{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:27:23Z","timestamp":1790623643832,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,27]]},"DOI":"10.7759\/cureus.61176","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T15:36:57Z","timestamp":1716824217000},"source":"Crossref","is-referenced-by-count":1,"title":["Imatinib-Induced Bone Marrow Aplasia in Chronic Myelogenous Leukemia"],"prefix":"10.7759","author":[{"given":"Ratika","family":"Dogra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallabh","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay R","family":"Shelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1721727X231158468","article-title":"matinib-induced severe hematological toxicity: rolonged myelosuppression resulting from extraordinary sensitivity in an old age","volume":"21","author":"Xu J","year":"2023","unstructured":"Xu J, Ju B, Yang XD, Xiu NN, Zhao XC. matinib-induced severe hematological toxicity: rolonged myelosuppression resulting from extraordinary sensitivity in an old age. Eur J Inflamm. 2023, 21:10.1177\/1721727X231158468","journal-title":"Eur J Inflamm"},{"key":"ref2","article-title":"Imatinib","author":"Flynn JP","year":"2023","unstructured":"Flynn JP, Gerriets V. Imatinib. StatPearls Publishing, Treasure Island, USA; 2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0110","article-title":"Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?","volume":"2","author":"Goldman J","year":"2005","unstructured":"Goldman J. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?. Nat Clin Pract Oncol. 2005, 2:126-7. 10.1038\/ncponc0110","journal-title":"Nat Clin Pract Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1309\/NR81-VCU0-CKW1-4HT9","article-title":"ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response","volume":"117","author":"Hasserjian RP","year":"2002","unstructured":"Hasserjian RP, Boecklin F, Parker S, et al.. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol. 2002, 117:360-7. 10.1309\/NR81-VCU0-CKW1-4HT9","journal-title":"Am J Clin Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S5775","article-title":"Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase","volume":"4","author":"Mughal TI","year":"2010","unstructured":"Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics. 2010, 4:315-23. 10.2147\/BTT.S5775","journal-title":"Biologics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot F","year":"2004","unstructured":"Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004, 9:271-81. 10.1634\/theoncologist.9-3-271","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14092","article-title":"Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?","volume":"85","author":"E\u015fkazan AE","year":"2019","unstructured":"E\u015fkazan AE. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?. Br J Clin Pharmacol. 2019, 85:2241-3. 10.1111\/bcp.14092","journal-title":"Br J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"94","author":"Rea D","year":"2015","unstructured":"Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol. 2015, 94:S149-58. 10.1007\/s00277-015-2318-y","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4861673","article-title":"Aplasia in chronic phase CML post-TKI therapy: a management dilemma","volume":"2019","author":"Ramdial JL","year":"2019","unstructured":"Ramdial JL, Aguirre LE, Ali RA, Swords R, Goodman M. Aplasia in chronic phase CML post-TKI therapy: a management dilemma. Case Rep Hematol. 2019, 2019:4861673. 10.1155\/2019\/4861673","journal-title":"Case Rep Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211052030","article-title":"Aplastic anemia secondary to tyrosine kinase inhibitor therapy in a patient with chronic myeloid leukemia","volume":"28","author":"Kassar O","year":"2022","unstructured":"Kassar O, Mallek R, Ben Said F, Kallel F, Ksouda K, Khabir A, Elloumi M. Aplastic anemia secondary to tyrosine kinase inhibitor therapy in a patient with chronic myeloid leukemia. J Oncol Pharm Pract. 2022, 28:504-7. 10.1177\/10781552211052030","journal-title":"J Oncol Pharm Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500046778","article-title":"Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia","volume":"46","author":"Lokeshwar N","year":"2005","unstructured":"Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma. 2005, 46:781-4. 10.1080\/10428190500046778","journal-title":"Leuk Lymphoma"},{"key":"ref12","article-title":"Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy (Article in Japanese)","volume":"43","author":"Sumi M","year":"2002","unstructured":"Sumi M, Tauchi T, Shimamoto T, Sshida G, Nakajima A, Ito Y, Ohyashiki K. Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy (Article in Japanese). Rinsho Ketsueki. 2002, 43:868-70.","journal-title":"Rinsho Ketsueki"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_1594_20","article-title":"Severe persistent marrow aplasia in chronic myeloid leukemia (CML): an unusual complication of imatinib","volume":"19","author":"Madabhavi I","year":"2023","unstructured":"Madabhavi I, Patel A, Anand A, Panchal H. Severe persistent marrow aplasia in chronic myeloid leukemia (CML): an unusual complication of imatinib. J Cancer Res Ther. 2023, 19:335-9. 10.4103\/jcrt.JCRT_1594_20","journal-title":"J Cancer Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.11.017","article-title":"Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"29","author":"Chng WJ","year":"2005","unstructured":"Chng WJ, Tan LH. Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia. Leuk Res. 2005, 29:719-20. 10.1016\/j.leukres.2004.11.017","journal-title":"Leuk Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.209","article-title":"Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?","volume":"21","author":"Cashen A","year":"2003","unstructured":"Cashen A, DiPersio JF, Khoury H. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?. J Clin Oncol. 2003, 21:4255-6. 10.1200\/JCO.2003.99.209","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed TB","year":"2004","unstructured":"Sneed TB, Kantarjian HM, Talpaz M, et al.. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004, 100:116-21. 10.1002\/cncr.11863","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/256565-imatinib-induced-bone-marrow-aplasia-in-chronic-myelogenous-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T15:37:01Z","timestamp":1716824221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/256565-imatinib-induced-bone-marrow-aplasia-in-chronic-myelogenous-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.61176","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}